

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Soumya P. Sahoo, et al.		
Serial No.:	TO BE ASSIGNED	Case No.:	20768
Filed:	October 29, 2001		
For:	BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS		

Art Unit:
To Be Assigned

Examiner:
To Be Assigned

Honorable Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the specification by adding the following sentence after the title and before the Field of the Invention section:

-- CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority from US Provisional Application No. 60/244,698, filed on October 31, 2000, which is incorporated by reference into this application in its entirety.--

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT October 29, 2001

EXPRESS MAIL NO. EL523910388US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY Linda Zherer
DATE October 29, 2001

In the Claims

Please also amend Claims 14, 27, 31, 32, and 35 so that they read as shown below:

14. (Amended) A compound having formula I as recited in Claim 1, wherein R₃, R₅, R₆, R₇, R₈, R₉, and R₁₀ are H; R₂ is Cl or F; and R₁ is C₁₋₄alkyl, Cl or F, where C₁₋₄alkyl is linear or branched and is optionally substituted with 1-5 F.

27. (Amended) A compound having formula I as recited in Claim 1, wherein R₃, R₅, R₆, R₇, R₈, R₉, and R₁₀ are H; R₁ is C₁₋₄alkyl, Cl or F; and R₂ is Cl or F.

31. (Amended) A compound as recited in Claim 1, wherein the stereochemistry at the 2-position of the benzopyranyl ring is R.

32. (Amended) A compound as recited in Claim 1, wherein the stereochemistry at the 2-position of the benzopyranyl ring is S.

35. (Amended) A pharmaceutical composition comprising a compound as identified in Claim 1 and a pharmaceutically acceptable carrier.


Serial No.: To be assigned
Case No.: 20768
Page 3

REMARKS

The amendments to the claims change the dependency of Claims 14, 27, 31, 32, and 35 so that they depend on Claim 1 and are not multiply dependent. The changes that were made to these claims are shown on the attachment.

This application is being filed under 35 U.S.C. 1.53(b) and claims priority from the above cited Provisional Applications. Examination on the merits is respectfully requested.

Respectfully submitted,

By 
James L. McGinnis
Reg. No. 34,387
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0641

Date: October 29, 2001

Attachment Showing Amendments to Claims

14. (Amended) A compound having formula I as recited in Claim 1, [any one of Claims 1-13,] wherein R³, R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ are H; R² is Cl or F; and R¹ is C₁₋₄alkyl, Cl or F, where C₁₋₄alkyl is linear or branched and is optionally substituted with 1-5 F.

27. (Amended) A compound having formula I as recited in Claim 1, [any one of Claims 1-26,] wherein R³, R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ are H; R¹ is C₁₋₄alkyl, Cl or F; and R² is Cl or F.

31. (Amended) A compound as recited in Claim 1, [any one of Claims 1-30,] wherein the stereochemistry at the 2-position of the benzopyranyl ring is R.

32. (Amended) A compound as recited in Claim 1, [any one of Claims 1-30,] wherein the stereochemistry at the 2-position of the benzopyranyl ring is S.

35. (Amended) A pharmaceutical composition comprising a compound as identified in Claim 1 [any of Claims 1-34] and a pharmaceutically acceptable carrier.